The first drug shown to slow Alzheimer’s disease hit the U.S. market over a year ago, but sales have lagged, major hospital systems have taken months to start using it and some insurers have rejected coverage.
Doctors also expect some patients will hesitate to take Leqembi due to its limited impact and potential side effects. They say it will take years to learn how best to deploy the drug and that work must be done to improve diagnosis.
“This is the start of a very exciting journey,” said Dr. Ambar Kulshreshtha, a suburban Atlanta family physician focused on dementia patients.
More than 6 million Americans, and millions more worldwide, have Alzheimer’s disease, the most common cause of dementia. There’s no cure, but Leqembi clears a sticky brain protein called amyloid that’s a key indicator of Alzheimer’s.
Studies showed that it can delay the progression of the disease by a few months when given to people with mild symptoms. Some experts say the delay may be too subtle for patients to notice.
Related articles:
Related suggestion:
Latest review should 'put to bed' methane debate, minister saysBullying rife at Buller High School, students sayShortland Street: Fate of muchIceland violent volcanic flareSo, you want to be an MP? These are the careers most likely to lead to ParliamentVOX POPULI: Ruling may be near on how to best romanize JapaneseVOX POPULI: Rooting for the Sendai killifish that survived the 2011 tsunamiChinese warships sail around Japan as tensions rise ahead of G7 summitVOX POPULI: Seven years on, the Moritomo Gakuen scandal still unexplainedVOX POPULI: Rooting for the Sendai killifish that survived the 2011 tsunami
3.0225s , 6496.421875 kb
Copyright © 2024 Powered by It's the first drug shown to slow Alzheimer's. Why is is it off to a slow start? ,Global Glossary news portal